From a Radiological Society of North America release:

The TACT Pivotal study of MRI-guided TULSA for whole-gland ablation in men with localized prostate cancer met its primary PSA endpoint in 96% of patients, with low rates of severe toxicity and residual GG2 disease. MRI at 12mo detected residual disease with NPV of 93%.

The new technique is called MRI-guided transurethral ultrasound ablation (TULSA) and has been under development for a number of years. The minimally invasive technology involves a rod that enters the prostate gland via the urethra and emits highly controlled sound waves in order to heat and destroy diseased tissue, while leaving healthy tissue unharmed.

To read more: https://press.rsna.org/pressrelease/2019_resources/2129/abstract.pdf